摘要
目的提高中药上市企业的综合竞争力。方法基于68家中药上市企业2014年至2018年的平行面板数据,运用全局主成分分析法分析其综合竞争力。结果偿债能力、盈利能力、营运能力和发展能力是评价企业综合竞争力的重要指标;中药上市企业整体综合竞争力可观,但各方面的能力发展不均衡且企业间差距显著。结论中药上市企业应通过优化资产结构以改善偿债能力,推动中药研发以提高盈利营运能力,协调竞争力指标以提高整体能力,推进医药电商及品牌影响力等途径提升企业综合竞争力。
Objective To improve the comprehensive competitiveness of listed traditional Chinese medicine(TCM)enterprises.Methods Based on the parallel panel data of 68 listed TCM enterprises from 2014 to 2018,the comprehensive competitiveness was analyzed by using the global principal component analysis method.Results Debt-paying ability,profitability,operation ability and development ability were the important indexes to evaluate the comprehensive competitiveness of an enterprise.The overall comprehensive competitiveness of listed TCM enterprises was considerable,but the development of capabilities in all aspects was uneven and the gap among enterprises was significant.Conclusion The listed TCM enterprises should optimize the asset structure to improve their debt-paying ability,promote the research and development of TCM to improve their profitability,coordinate the competitiveness indexes to improve their overall ability,and promote the pharmaceutical e-commerce and brand influence of medicine to enhance their comprehensive competitiveness.
作者
赫玉芳
于露
刘金萍
崔严尹
宁春雪
夏昉
HE Yufang;YU Lu;LIU Jinping;CUI Yanyin;NING Chunxue;XIA Fang(School of Health Management,Changchun University of Chinese Medicine,Changchun,Jilin,China 130117)
出处
《中国药业》
CAS
2020年第22期10-13,共4页
China Pharmaceuticals
基金
吉林省科技发展计划项目[20190802003ZG]。
关键词
全局主成分分析法
中药上市企业
综合竞争力
global principal component analysis
listed traditional Chinese medicine enterprise
comprehensive competitiveness
